Epidermolysis bullosa House Austria and Epidermolysis bullosa clinical network: Example of a centre of expertise implemented in a European reference network to face the burden of a rare disease

Wiener Klinische Wochenschrift

Volumn 129, Issue 1-2, 2017, Pages 1-7

  Laimer, Martin ^a   Pohla Gubo, Gabriela ^a   Diem, Anja ^a   Prodinger, Christine ^a   Bauer, Johann W ^a   Hintner, Helmut ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

CLINET; EB House; Epidermolysis bullosa; European Union; Orphan diseases

Indexed keywords

ARTICLE; AUSTRIA; CROSS LINKING; EPIDERMOLYSIS BULLOSA; EUROPEAN UNION; HEALTH ECONOMICS; HUMAN; PATIENT CARE; RARE DISEASE; EVIDENCE BASED MEDICINE; GENERAL HOSPITAL; NONBIOLOGICAL MODEL; ORGANIZATION AND MANAGEMENT; PUBLIC RELATIONS; RARE DISEASES;

AUSTRIA; EPIDERMOLYSIS BULLOSA; EUROPEAN UNION; EVIDENCE-BASED MEDICINE; HOSPITALS, GENERAL; HUMANS; INTERINSTITUTIONAL RELATIONS; MODELS, ORGANIZATIONAL; PATIENT CARE MANAGEMENT; PATIENT CARE TEAM; RARE DISEASES;

EID: 85001114614     PISSN: 00435325     EISSN: 16137671     Source Type: Journal    
DOI: 10.1007/s00508-016-1133-3     Document Type: Article

References (16)

1. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products.
2. www.orpha.net. Accessed October 10, 2016.
3. Commission Communication 697 to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions on Rare Diseases: Europe’s Challenges 11 Nov 2008.
4. Commission Communication 697 European Council. Council Recommendation on an action in the field of rare diseases (2009/C 151/02), 8 June 2009.
5. http://www.goeg.at/de/NAP_se.html. Accessed October 10, 2016.
6. EUCERD, EUROPLAN. 2009 report on initiatives and incentives in the field of rare diseases of the European Union Committee of experts on rare diseases. In: Aymé S, Rodwell C, editors. July 2010. doi:10.2772/11801
7. EUCERD. Recommendations on core indicators for rare disease national plans/strategies. 6 June. 2013.
8. EUCERD. Recommendations for quality criteria for centres of expertise for rare diseases in member states. 24 October. 2011.
9. EUCERD. Recommendations on rare diseases european reference networks. 31 January. 2013.
10. Fine JD, Hintner H. (editors) Life with Epidermolysis Bullosa (EB): etiology, diagnosis, multidisciplinary care and therapy. Wien: Springer; 2008.
11. High Level Group, Article 15 of the proposal of Directive of the European Parliament and of the Council on the application of patients’ rights in cross-border healthcare (COM(2008)414; Regulation (EC) No 883/2004)
12. EU rare diseases Task Force. Report to the High Level Group ‘Contribution to policy shaping: For a European collaboration on health services and medical care in the field of RD. 2006.
13. www.europlanproject.eu. Accessed October 10, 2016.
14. Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med. 2010;363(6):532–41.
15. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361(12):1164–72.
16. Wally V, Kitzmueller S, Lagler F, et al. Topical diacerein for epidermolysis bullosa: a randomized controlled pilot study. Orphanet J Rare Dis. 2013;8:69. doi:10.1186/1750-1172-8-69.